Stocks and Investing Stocks and Investing
Tue, January 4, 2022
Mon, January 3, 2022

Edward Tenthoff Upgraded (ALNY) to Buy and Increased Target to $208 on, Jan 3rd, 2022


Published on 2024-10-27 19:06:49 - WOPRAI, Edward Tenthoff
  Print publication without navigation


Edward Tenthoff of Piper Sandler, Upgraded "Alnylam Pharmaceuticals, Inc." (ALNY) to Buy and Increased Target from $181 to $208 on, Jan 3rd, 2022.

Edward has made no other calls on ALNY in the last 4 months.



There are 8 other peers that have a rating on ALNY. Out of the 8 peers that are also analyzing ALNY, 1 agrees with Edward's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Mani Foroohar of "SVB Leerink" Maintained at Hold with Increased Target to $108 on, Thursday, October 28th, 2021


These are the ratings of the 7 analyists that currently disagree with Edward


  • Joseph Stringer of "Needham" Maintained at Strong Buy with Increased Target to $205 on, Monday, November 22nd, 2021
  • Luca Issi of "RBC Capital" Upgraded from Hold to Buy and Increased Target to $225 on, Monday, November 22nd, 2021
  • Salveen Richter of "Goldman Sachs" Upgraded from Hold to Strong Buy and Held Target at $273 on, Monday, November 22nd, 2021
  • Leland Gershell of "Oppenheimer" Upgraded from Hold to Buy and Held Target at $200 on, Monday, November 1st, 2021
  • Keay Nakae of "Chardan Capital" Maintained at Strong Buy with Increased Target to $200 on, Friday, October 29th, 2021
  • David Lebowitz of "Morgan Stanley" Maintained at Buy with Decreased Target to $226 on, Friday, October 29th, 2021
  • Esther Rajavelu of "UBS" Upgraded from Hold to Strong Buy and Increased Target to $215 on, Monday, October 4th, 2021
Contributing Sources